Browse 100+ evidence-based profiles with community ratings, dosage guides, and safety information.
Start ExploringPublished 28 March 2026
Cerebrolysin is a unique preparation of brain-derived peptides and free amino acids obtained from purified porcine (pig) brain tissue through controlled enzymatic hydrolysis. Developed in Austria by EVER Neuro Pharma, it contains a mixture of low-molecular-weight neuropeptides (approximately 25% by weight) and free amino acids (approximately 75%) that mimic the activity of naturally occurring neurotrophic factors. It is one of the most extensively studied neuropeptide preparations in the world, with over 200 clinical trials and a regulatory approval history spanning more than 40 countries.
Unlike most nootropics that can be taken orally, Cerebrolysin must be administered by intramuscular (IM) or intravenous (IV) injection because its peptide components would be destroyed by digestive enzymes. This injection requirement makes it one of the most "serious" interventions in the nootropic world - it is not a casual supplement but a pharmaceutical-grade preparation with a substantial clinical evidence base.
Important: Cerebrolysin is a prescription medication in many countries and requires medical supervision for administration. It is not approved by the MHRA (UK) or FDA (US) but is registered in over 40 countries including Austria, Germany, Russia, China, and South Korea. This guide is for informational purposes only. Intramuscular and intravenous injections should only be administered by or under the guidance of a qualified healthcare professional.
Cerebrolysin's peptide fraction contains fragments that mimic the biological activity of endogenous neurotrophic factors, particularly Brain-Derived Neurotrophic Factor (BDNF), Nerve Growth Factor (NGF), Glial-Derived Neurotrophic Factor (GDNF), and Ciliary Neurotrophic Factor (CNTF). Unlike recombinant neurotrophic factors (which are large proteins that cannot cross the blood-brain barrier), Cerebrolysin's low-molecular-weight peptides cross the BBB readily after systemic administration, reaching therapeutically relevant brain concentrations within 30 minutes.
This neurotrophic activity promotes neuronal survival, stimulates axonal sprouting (the growth of new neural connections), enhances synaptic plasticity, and supports neurogenesis (the birth of new neurons) in the hippocampus. These are the fundamental biological processes required for learning, memory, and recovery from brain injury.
Cerebrolysin provides multi-layered neuroprotection through several mechanisms:
Beyond neuroprotection, Cerebrolysin directly enhances synaptic function. It increases the density of dendritic spines (the postsynaptic structures where most excitatory synapses form), enhances long-term potentiation (LTP, the cellular mechanism of memory formation), and modulates neurotransmitter systems including acetylcholine, dopamine, and serotonin. These effects are relevant not only to recovery from brain injury but also to cognitive enhancement in healthy individuals.
Stroke recovery is Cerebrolysin's most extensively studied indication. A 2017 meta-analysis published in Drugs analysed 6 RCTs involving 1,649 stroke patients and found that Cerebrolysin (30-50 mL IV daily for 10-21 days, initiated within 72 hours of stroke onset) significantly improved early neurological recovery and functional outcomes compared to placebo. The CASTA trial (1,070 patients) and the CERE-LYSE trial confirmed these results, showing improvements in the NIH Stroke Scale and Barthel Index scores.
The benefits are most pronounced when treatment begins within 24-72 hours of stroke onset, during the critical window when neuroprotection and neurotrophic support can salvage ischaemic penumbra tissue (the region surrounding the stroke core that is damaged but not yet dead).
A 2016 RCT published in CNS Drugs studied Cerebrolysin (50 mL IV daily for 10 days) in 142 patients with moderate-to-severe TBI. The Cerebrolysin group showed significantly better recovery on the Glasgow Outcome Scale at 90 days. The neurotrophic and anti-excitotoxic mechanisms are particularly relevant in TBI, where secondary injury from excitotoxicity and inflammation often causes more damage than the initial impact.
Multiple RCTs have evaluated Cerebrolysin in Alzheimer's disease. A 2015 Cochrane-style systematic review analysed 6 trials involving 772 patients and found that Cerebrolysin (10-30 mL IV daily for 4-6 weeks) produced significant improvements in global clinical impression and cognitive function scores (ADAS-cog) compared to placebo, with effects persisting for 3-6 months after treatment courses. A 2017 study in Journal of Alzheimer's Disease confirmed improvements in both cognitive function and daily living activities.
The mechanism differs from standard Alzheimer's drugs (cholinesterase inhibitors): while donepezil merely preserves existing acetylcholine, Cerebrolysin promotes neuronal survival, synaptic repair, and neuroplasticity - addressing the disease process rather than just the symptoms. However, Cerebrolysin is not a cure, and benefits are temporary without repeated treatment courses.
A smaller body of evidence supports cognitive benefits in healthy adults. A 2011 study in Clinical Psychopharmacology and Neuroscience found that Cerebrolysin improved memory consolidation and cognitive flexibility in healthy volunteers. User reports from the nootropic community consistently describe improvements in verbal fluency, working memory, mental clarity, and learning speed during and after treatment courses. However, large-scale RCTs in healthy populations are lacking.
Clinical protocols use IV infusion (diluted in 100-250 mL normal saline, infused over 15-60 minutes) for doses above 10 mL. IV administration achieves higher peak concentrations and is standard in hospital settings.
For cognitive enhancement, lower doses administered intramuscularly are the standard approach. IM injection is technically simpler than IV infusion and can be self-administered (though medical supervision is recommended). Doses above 5 mL should be split between two injection sites. Many users report cumulative benefits over the course, with the most noticeable effects appearing around days 5-10.
Cerebrolysin has an established safety profile from over 200 clinical trials involving tens of thousands of patients. A 2017 safety meta-analysis found that the overall incidence of adverse events was comparable to placebo. The most commonly reported side effects are:
Cerebrolysin is manufactured exclusively by EVER Neuro Pharma (Austria). Genuine product comes in amber glass ampoules (1 mL, 5 mL, 10 mL, or 20 mL). It is available by prescription in countries where it is registered (Austria, Germany, Russia, China, South Korea, and many others). In the UK and US, where it is not registered, obtaining it requires importing from countries where it is available - typically through international pharmacies or medical tourism.
The most potent neurotrophic combination available. Cerebrolysin provides broad neurotrophic factor mimicry while Semax specifically upregulates BDNF through a complementary mechanism. Used by advanced biohackers for maximal neuroplasticity, stroke recovery, or cognitive recovery after brain injury. Not for casual use.
Cerebrolysin promotes neuronal survival and synaptic growth while citicoline provides the phospholipid building blocks (phosphatidylcholine) and acetylcholine precursors needed to build and maintain the new connections. A logical combination that addresses both the growth signal and the construction materials.
Cerebrolysin occupies a unique position in the nootropic landscape: it is one of the most extensively studied neuropeptide preparations, with over 200 clinical trials supporting its efficacy for stroke recovery, TBI, and Alzheimer's disease. Its multi-neurotrophic mechanism (mimicking BDNF, NGF, GDNF, and CNTF simultaneously) is unmatched by any oral supplement. The main barriers to use are the injection requirement, limited availability in Western countries, and cost. For those willing to navigate these challenges, Cerebrolysin offers a level of neurotrophic support that is qualitatively different from oral nootropics.
For those seeking non-injectable neurotrophic support, Lion's Mane (NGF) and Semax nasal spray (BDNF) provide the most accessible alternatives. For more on our Semax Nasal Spray Guide, see the companion article. For combining nootropics effectively, our Stacking Guide covers safety principles.
Cerebrolysin is a brain-derived neuropeptide preparation manufactured from purified porcine (pig) brain tissue. It contains a mixture of low-molecular-weight peptides that mimic the activity of natural neurotrophic factors (BDNF, NGF, GDNF, CNTF). It is administered by injection (intramuscular or intravenous) and is registered as a pharmaceutical in over 40 countries for stroke recovery, traumatic brain injury, and Alzheimer's disease. It has over 200 clinical trials supporting its efficacy. It is also used off-label for cognitive enhancement.
The clinical evidence is strongest for neurological conditions (stroke, TBI, Alzheimer's), where multiple large RCTs show significant benefits. For cognitive enhancement in healthy individuals, the evidence is more limited but supportive - a 2011 study found improvements in memory consolidation and cognitive flexibility in healthy volunteers. User reports from the nootropic community consistently describe improvements in verbal fluency, mental clarity, and learning speed. The neurotrophic mechanisms (promoting synaptic growth and neuroplasticity) provide a plausible basis for cognitive enhancement.
Cerebrolysin is administered by intramuscular (IM) injection for doses up to 5 mL, or by intravenous (IV) infusion for larger doses (10-50 mL, diluted in normal saline). It cannot be taken orally because the peptides would be destroyed by digestive enzymes. For cognitive enhancement, 5 mL IM daily for 10-20 days is the typical protocol. IM injections are administered into the upper outer buttock or deltoid muscle using a 23-25 gauge needle. Medical supervision is recommended, particularly for first-time users and IV administration.
Cerebrolysin has a well-established safety profile from over 200 clinical trials involving tens of thousands of patients. A meta-analysis found adverse event rates comparable to placebo. Common side effects are mild: injection site pain, occasional dizziness, and rare headache or insomnia. It is contraindicated in epilepsy (may lower seizure threshold), severe kidney impairment, and allergy to porcine products. The main safety concern for non-medical users is sourcing - counterfeit products exist, so only purchase from verified sources with batch documentation.
Both are neurotrophic peptide nootropics but differ significantly. Cerebrolysin provides a broader neurotrophic profile (mimicking BDNF, NGF, GDNF, and CNTF) and has a much larger clinical evidence base (200+ trials). Semax primarily upregulates BDNF and is administered as a nasal spray (far more convenient than injection). Semax offers daily cognitive enhancement; Cerebrolysin is used in 10-20 day treatment courses. Many advanced users combine both for maximum neurotrophic support. For accessibility and ease of use, Semax is the practical choice; for maximum neuroprotective potency, Cerebrolysin is superior.